Premium
Rapamycin protects against early brain injury independent of cerebral blood flow changes in a mouse model of subarachnoid haemorrhage
Author(s) -
Sasaki Kazumasu,
Yamamoto Shuzo,
Mutoh Tatsushi,
Tsuru Yoshiharu,
Taki Yasuyuki,
Kawashima Ryuta
Publication year - 2018
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12950
Subject(s) - hypoactivity , pi3k/akt/mtor pathway , cerebral blood flow , hypoxia (environmental) , neuroprotection , medicine , anesthesia , ischemia , pharmacology , chemistry , signal transduction , biochemistry , organic chemistry , oxygen
Summary We evaluated the neuroprotective role of rapamycin, a mammalian target of rapamycin ( mTOR ) kinase inhibitor, in cerebral ischaemia and locomotor function in a mouse model of subarachnoid haemorrhage ( SAH ). Pretreatment with rapamycin, an mTOR kinase inhibitor, resulted in better recovery from cerebral hypoxia early after SAH than control ( P < .05), while the values of peak flow velocity in the middle cerebral artery did not change significantly ( P > .05). Average distance travelled and the ratio of central‐area distance/total travelled distance determined by open‐field test after day 14 was significantly higher in mice pretreated with rapamycin than in control mice ( P < .05). Inhibition of the mTOR pathway could be protective against post‐ SAH early brain injury, ameliorating brain tissue hypoxia and locomotor hypoactivity.